双鹭药业的前世今生：营收、净利润行业排名领先，负债率远低于行业平均

Core Viewpoint - 双鹭药业 is a leading enterprise in the research and production of genetic engineering drugs in China, focusing on the development of related pharmaceuticals and demonstrating strong technical research advantages [1] Group 1: Business Performance - In Q3 2025, 双鹭药业 reported revenue of 459 million yuan, ranking 84th out of 110 in the industry, with the industry leader, 华东医药, generating 32.664 billion yuan [2] - The net profit for the same period was 141 million yuan, placing the company 44th in the industry, while the top performer, 恒瑞医药, achieved a net profit of 5.76 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, 双鹭药业's debt-to-asset ratio was 5.44%, significantly lower than the industry average of 35.26%, indicating strong solvency [3] - The gross profit margin for the same period was 61.60%, higher than the industry average of 57.17%, reflecting good profitability [3] Group 3: Executive Compensation - The chairman, 徐明波, received a salary of 429,400 yuan in 2024, an increase of 44,400 yuan from the previous year [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 6.35% to 54,800, while the average number of circulating A-shares held per shareholder increased by 6.78% to 15,600 [5] - Among the top ten circulating shareholders, 香港中央结算有限公司 held 12.1213 million shares, an increase of 3.4299 million shares from the previous period [5]